Australia
Seeing Machines Announces Groundbreaking Impairment Detection Capability
As MADD marks its 45th anniversary, Seeing Machines unveils technology to detect alcohol impaired driving. CANBERRA, Australia, Sept. 9, 2025 /PRNewswire/ -- As hundreds of people gather inWashington, D.C. to remember loved ones killed or injured by drunk drivers, Seeing Machines announced a new...
Melitta Group becomes official coffee partner of Real Madrid
* Cooperation with one of the world's most successful soccer clubs creates visibility among the largest sports fan base worldwide * Melitta will be the exclusive coffee partner of Real Madrid for the next five years * Extensive communications and marketing package agreed for the women's and ...
$1M Forever: Halo's Enterprise Revolution Launches for Select Global Organisations
STOWMARKET, England, Sept. 8, 2025 /PRNewswire/ -- Halo, the independent leader in Enterprise Service Management (ESM), today announced"$1M Forever", a bold new enterprise package that guarantees organisations predictable, fixed ESM licensing costs for life - while delivering far faster deploymen...
Remplir™ Study Delivers Compelling 81% Success Rate
Data to support US sales roll out and EU + UK regulatory submissions * Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. * Real World Evidence (RWE) patient data collected in the study confirms Ortho...
Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states
Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet for...
China Accreditation Test for Translators and Interpreters Becomes the World's Largest Translation Test
BEIJING, Aug. 25, 2025 /PRNewswire/ -- The China Accreditation Test for
Translators and Interpreters (CATTI) is a state-level vocational qualification
examination administered by CICG Academy of Translation and Interpretation.
Heartbeats Launches Digital Wellness Platform Led by World-Renowned Heart Specialist Dr. Hosen Kiat
SYDNEY, Aug. 22, 2025 /PRNewswire/ -- In an online world awash with wellness
fads and misinformation, one of the world's most cited cardiologists has
decided to step in.Dr Hosen Kiat
FDA clearance of Salix® Coronary Plaque module
Significantly expands U.S. commercial opportunity with ability to charge fees per scan assessed Investor Webinar - 11.30am AEST (9.30am AWST) on 22 August 2025 PERTH, Australia, Aug. 21, 2025 /PRNewswire/ -- Artrya Limited (ASX: AYA) ( Artrya or the Company), a medical technology company commerc...
Karpowership and Seatrium Launch LNGTS Americas and Sign LoI for Next-Gen Floating Power Projects
ISTANBUL, Aug. 14, 2025 /PRNewswire/ -- Karpowership and Seatrium have celebrated the naming ofKaradeniz LNGTS Americas, the fifth member of Karpowership's LNG Terminal Ship (LNGTS) fleet. The ceremony also saw both companies sign a strategic partnership to convert the Karpowership's next-genera...
Alpha Global partners with LIO to redefine Mental Health Care in Australia
New platform boosts patient experience and safety, reduces clinician burden, and unlocks operational insight across inpatient mental health hospitals SYDNEY, Aug. 14, 2025 /PRNewswire/ -- Alpha Global, a trusted provider of technology-driven solutions for healthcare and care providers inAustralia...
Australia's Prestigious Darwin Aboriginal Art Fair returns for its 19th Year, and you can access it online!
DARWIN, Australia, Aug. 7, 2025 /PRNewswire/ -- The world-renowned Darwin
Aboriginal Art Fair (DAAF) returns to Larrakia Country in Darwin,Australia, and
is online fromAugust 8 to 10 (2025), celebrating Australian Aboriginal and
Torres Strait Islander art, design and culture.
X‑Design Tops Product Hunt with One-Click Lifestyle Product Photos
— A new AI tool that helps small Home Décor brands create realistic listing
images without a studio
SYDNEY, Aug. 7, 2025 /PRNewswire/ -- X‑Design
Vmake AI Talking Video Editor: The All-in-One Solution for Talking Videos, Empowering Diverse Creators
SYDNEY, Aug. 7, 2025 /PRNewswire/ -- Vmake
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIP...
A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US
All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months SYDNEY, July 22, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is encouraging individu...
Co-PSMA trial: Recruitment successfully completed
SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of d...
Mindsprint enhances ProcureSPRINT™ with Agentic AI to unlock up to 15% in procurement cost efficiencies
SINGAPORE, July 9, 2025 /PRNewswire/ -- Mindsprint
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...
Week's Top Stories
Most Reposted
Agoda and Singapore Tourism Board Expand Partnership to Boost Demand and Tech Transformation in Tourism
[Picked up by 321 media titles]
2026-08-14 10:00PARKROYAL COLLECTION Marina Bay, Singapore Named Among Singapore's Top 10 Hotels by Travel + Leisure and Featured on 50 Best Discovery
[Picked up by 318 media titles]
2026-08-14 12:27Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 316 media titles]
2026-08-13 12:00Agoda Unveils Agoda Partner Portal as the Refreshed Platform's Role in Property Management Expands
[Picked up by 312 media titles]
2026-08-17 09:00DayOne Launches Singapore's First Biological Data Center Prototype with Cortical Labs and NUS Medicine
[Picked up by 300 media titles]
2026-08-17 10:00